Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
The organoids could be grown to contain cellular features of the original tissue samples, enabling them to better mimic what occurs in the body than two-dimensional cultures.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.
Currently available under a soft launch, the tool can provide information about the prevalence of cancer risk mutations based on patients' demographics.
